

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CARsgen Therapeutics Holdings Limited

科濟藥業控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2171)

VOLUNTARY ANNOUNCEMENT APPOINTMENT OF SENIOR MANAGEMENT

This announcement is made by CARsgen Therapeutics Holdings Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**” or “**CARsgen**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) announces that Dr. Sylvie Peltier (“**Dr. Peltier**”) has been appointed as Senior Vice President of Global Regulatory Affairs of the Company with effect from October 31st, 2022. She will be responsible for developing global regulatory strategies, leading and driving the Company’s regulatory affairs activities and initiatives in support of IND/CTA/BLA filing and approval of developmental products globally.

The biographical details of Dr. Peltier are set out below:

Dr. Peltier, aged 58, has extensive global leadership and hands-on experiences in Clinical and CMC Regulatory Affairs across several multinational pharmaceutical and biopharmaceutical companies. Prior to joining CARsgen, Dr. Peltier served as Vice President, Head of US Regulatory Affairs at MorphoSys US Inc (NASDAQ: MOR) since 2020, and as Head of Regulatory Affairs at Servier Pharmaceuticals LLC from 2018. Before joining Servier Pharmaceuticals LLC, Dr. Peltier served at Cephalon since 2007, an international biopharmaceutical company which was acquired later by TEVA Pharmaceuticals Industries Ltd (NYSE: TEVA), holding various positions from Senior Director, Europe Regulatory Affairs, CNS/Pain and CMC, Senior Director, US Regulatory Affairs, to Senior Director, Clinical Search Evaluation and Due Diligence. Previously, Dr. Peltier worked at Pfizer Regulatory Affairs from 1995.

Dr. Peltier earned a Diploma of Pharmacy Doctorate and a Diploma of Graduated Specialized Studies (DESS) in Health Law from University of Paris XI in Paris, France.

The Board would like to express its warmest welcome to Dr. Peltier.

DEFINITIONS

“BLA”	biologics license application
“CMC”	chemistry, manufacturing, and controls processes in the development, licensure, manufacturing, and ongoing marketing of pharmaceutical products
“CNS”	central nervous system
“CTA”	clinical trial application
“IND”	investigational new drug or investigational new drug application, also known as clinical trial application in China
“US”	the United States of America, its territories, its dependencies and all areas subject to its jurisdiction

By order of the Board
CARsgen Therapeutics Holdings Limited
Dr. Zonghai LI
Chairman

Hong Kong, October 31, 2022

As at the date of this announcement, the board of directors of the Company comprises Dr. Zonghai LI, Dr. Huamao WANG and Dr. Hua JIANG as executive Directors; Mr. Bingsen GUO, Mr. Huaqing GUO and Mr. Ronggang XIE as non-executive Directors; Dr. Chunhai FAN, Dr. Guangmei YAN and Mr. Tak Young SO as the independent non-executive Directors.

In the case of inconsistency, the English text of this announcement shall prevail over the Chinese text.